Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. - Wikidata - awgldk - TriplyDB

Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders.

Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders.

http://www.wikidata.org/entity/Q45899921

about

How Should Cancer Surveillance in Primary Sclerosing Cholangitis Be Performed?Cancer biomarker discovery for cholangiocarcinoma: the high-throughput approaches Primary sclerosing cholangitis: diagnosis and treatment Cancer review: Cholangiocarcinoma Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management Seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease Proteomic Analysis of Vitreous Humor in Retinal Vein Occlusion 2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications Classical MALDI-MS versus CE-based ESI-MS proteomic profiling in urine for clinical applications.Angiopoietin-2 and biliary diseases: elevated serum, but not bile levels are associated with cholangiocarcinoma.Proteomics of vitreous humor of patients with exudative age-related macular degeneration Identification of urine biomarkers associated with lung adenocarcinoma.Treatment of autoimmune liver disease: current and future therapeutic options.Collagen peptides in urine: a new promising biomarker for the detection of colorectal liver metastases State-of-the-art nanoplatform-integrated MALDI-MS impacting resolutions in urinary proteomics.MicroRNAs in Serum and Bile of Patients with Primary Sclerosing Cholangitis and/or Cholangiocarcinoma.The Role of Biliary Carcinoembryonic Antigen-Related Cellular Adhesion Molecule 6 (CEACAM6) as a Biomarker in Cholangiocarcinoma.Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management.The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer.A capillary electrophoresis coupled to mass spectrometry pipeline for long term comparable assessment of the urinary metabolome.Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development.Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications.Primary Sclerosing Cholangitis: Current and Future Management Strategies.Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: Focus on Bladder Cancer.Novel diagnostic and prognostic biomarkers in biliary tract cancer.Clinical proteomics in obstetrics and neonatology.Application of capillary electrophoresis for the early diagnosis of cancer.CE-ESI-MS for bottom-up proteomics: Advances in separation, interfacing and applications.Advances in urinary proteome analysis and applications in systems biology.The diagnosis and treatment of cholangiocarcinoma Capillary zone electrophoresis on-line coupled to mass spectrometry: A perspective application for clinical proteomics.Primary sclerosing cholangitis: a clinical update.Deciphering the complexity of the cancer proteome for diagnostic applications.Greater Biosynthetic Liver Dysfunction in Primary Sclerosing Cholangitis Suggests Co-existent or Impending Cholangiocarcinoma.Advances in mass spectrometry-based cancer research and analysis: from cancer proteomics to clinical diagnostics.Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management.Analysis of U2 small nuclear RNA fragments in the bile differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders.Comparison of higher energy collisional dissociation and collision-induced dissociation MS/MS sequencing methods for identification of naturally occurring peptides in human urine.A combined bile and urine proteomic test for cholangiocarcinoma diagnosis in patients with biliary strictures of unknown origin.Anti-GP2 IgA: a biomarker for disease severity and/or cholangiocarcinoma in primary sclerosing cholangitis?

P2860

Q26782878-29C11584-92A5-414D-850C-AB4E12C3FE9D Q26821926-BAE27076-B70E-407E-B1EB-8DEBE8F1A862 Q26829216-B1367B7F-114E-4B4B-9F31-48B5155F87AF Q26865200-5632AA8A-15EB-49DB-860C-1B440948E82F Q27015831-5D671C06-96E9-48BA-9738-9F3F9C880248 Q28534235-849F3A17-13AC-4CF3-8575-87C0FEF90F21 Q28552292-70D387DA-0DFC-4F98-ADF0-88AB1CBC95AB Q30239808-9C7C65F6-F1D7-49C1-BA6D-996274E0DF14 Q31148183-CB0022BF-10B6-419D-BEF4-0871F41712BE Q33605089-C583BFB0-9DA3-435B-924D-B8C43D2CB261 Q33610106-E2D20428-33CA-4AB4-934E-0E093DE57FBB Q33888856-2F99FE9C-971A-4722-A809-966EE540D791 Q34342199-C921F441-DEE8-45D4-88B7-5417DDCD4A9E Q34970404-05150EE2-7887-48B8-A5C3-550019F12513 Q35570959-06272130-21AA-4EE8-8C95-FBE351C7D2FC Q35796897-0D011450-178E-4E46-8A6D-47249EE918E6 Q35956062-9BE03591-5035-4EB3-8C70-41C69D2AC25B Q36199767-BEDCA005-F405-489E-ABA2-022BFF4EF172 Q36683019-DE9F1006-1229-486E-97AA-B50A5D998D49 Q37303421-93EDC315-B647-4EAD-9297-32BA6454A59A Q37714579-08751A6B-91E9-4939-9C4C-F76CFA1A1647 Q38091336-354BD80D-576C-42C2-8BBF-EA2A9B2BE237 Q38107484-9BF65B5F-8BA8-4EE3-93B7-84371D20A1B2 Q38130892-6BA3FCB1-E487-498D-8A75-3DAC5F28CB61 Q38131056-F33B14F7-EF4C-44EA-9980-D04CE3633F9A Q38176934-F1BEFED6-CCA0-4C6F-82C4-CFDD29C7CEB5 Q38199367-FAAED19D-1779-441A-B190-B40531D31644 Q38213808-85CBD97C-9057-4EA9-90D9-1FDBD2E3BB8E Q38269864-470CBA5A-4136-4427-BD70-D843D20B04EE Q38269945-4D031BA1-B312-4983-99A1-F0B009BF21F8 Q38340351-B468D624-88EC-4AE6-A8EE-43B1402F1D62 Q38485235-6B79DCB0-77D7-46EC-9FB7-C59D9284617F Q38676337-55F90A3D-3FAA-4074-B045-BC4F2A209D84 Q38798747-BEE2304E-B1C6-45DA-A9D8-D598FD471847 Q38816181-850D213D-98FF-4523-BB5D-402EC6F35146 Q38906256-4F3D97A5-F09A-4C0E-8E3D-130CF2A040FE Q39259431-A5C5CE08-8805-4922-9830-75DBAC3FC218 Q41142978-9F97003E-B5DA-491A-ABD3-BB1E33D827C1 Q41303036-4AD885EA-1D77-4B52-96DD-3CCF5104783B Q41542251-650666A1-CF9A-4B4A-B082-9FE967B7E6B0

P2860

Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders.

http://www.wikidata.org/entity/Q45899921

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Urine proteomic analysis diffe ...... ther benign biliary disorders.

@en

Urine proteomic analysis diffe ...... ther benign biliary disorders.

@nl

type

label

Urine proteomic analysis diffe ...... ther benign biliary disorders.

@en

Urine proteomic analysis diffe ...... ther benign biliary disorders.

@nl

prefLabel

Urine proteomic analysis diffe ...... ther benign biliary disorders.

@en

Urine proteomic analysis diffe ...... ther benign biliary disorders.

@nl

P1433

Q45899921-3B1E17D0-C094-4797-8754-B0866920D5DB

P1476

Q45899921-BF34EDBF-6687-4DDC-A452-53BE1A5BF892

P2093

Q45899921-2AFD5EE9-7EA5-4021-BA27-EF55D863DA81

Q45899921-2DB0BAE2-84A1-4AF7-B4DF-077ED79DDA23

Q45899921-2EE1139D-7348-42BE-9F8F-E27FF15731D4

Q45899921-39D96F6D-9C75-4842-B229-12E7265A7C0C

Q45899921-3F9612D3-F286-41C8-A729-A204560FC80F

Q45899921-6C3E120D-AABB-46C2-971B-F0D52333E7F7

Q45899921-83C95A17-E785-4842-B57D-264ECD8C98BF

Q45899921-8E90731E-6474-4612-8F89-39B56004D227

P304

Q45899921-1A486F70-3F00-4209-85B6-BAB87337DC89

P31

Q45899921-8D4AF964-456F-4EE2-B42E-73DC6C5584C2

P356

Q45899921-6B6E250E-B6E7-405E-A6ED-8873077E956C

P407

Q45899921-0F6E67BE-DE96-42A3-8534-6C5390A51008

P433

Q45899921-E7A6AC10-9565-4436-8401-36B0CA34CA18

P478

Q45899921-4FE7C57B-D148-4265-928B-29A3D0841178

P50

Q45899921-5E860938-D28E-4B48-94FB-4CB819E3C96D

Q45899921-8A7BB239-38E1-4819-84C0-877F833C33FE

Q45899921-9A5970AF-8EE1-4AFD-8213-7C581975AD0E

P577

Q45899921-81CDEB0B-6D2D-44B3-9E08-9941879CB7D5

P698

Q45899921-0038D4B0-104B-4574-9411-BCF71595CBCB

P921

Q45899921-576F5CC6-11AD-4383-A00B-A005CFE0195C

Q45899921-7BE892F8-66C7-4530-9DA0-60A7B04E2665

P356

GUTJNL-2012-302047

P1433

P1476

Urine proteomic analysis diffe ...... ther benign biliary disorders.

@en

P2093

Ahmed A Negm

http://www.w3.org/2001/XMLSchema#string

Jochen Wedemeyer

http://www.w3.org/2001/XMLSchema#string

Michael P Manns

http://www.w3.org/2001/XMLSchema#string

Mohammed Dakna

http://www.w3.org/2001/XMLSchema#string

Ruben R Plentz

http://www.w3.org/2001/XMLSchema#string

Tim O Lankisch

http://www.w3.org/2001/XMLSchema#string

Tom H Karlsen

http://www.w3.org/2001/XMLSchema#string

William Mullen

http://www.w3.org/2001/XMLSchema#string

P304

122-130

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUTJNL-2012-302047

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P50

Tobias J. Weismüller

P577

2012-05-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22580416

http://www.w3.org/2001/XMLSchema#string

P921

cholangiocarcinoma